|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
2.54/1.74
|
企业价值
1.87B
|
资产负债 |
每股账面净值
9.56
|
现金流量 |
现金流量率
--
|
损益表 |
收益
60.00M
|
每股收益
--
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/18 11:25 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Itspipeline products include Rusfertide (PTG-300) and JNJ-2113. |